The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

GSK's chief executive, Emma Walmsley, accentuated the group's pipeline in comments on the results, pointing to "11 positive phase 3 trials reported so far this year and [...planned] launches for ...

GSK’s new asthma ... goals in a phase 1/2 trial in genetic disease AATD, and it wants to raise $500m to take it forward. Regulators have started reviews of GSK's depemokimab, aiming to become ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, ...

A 12-month interim analysis of the AGILE Phase III extension study confirms the long-term safety and efficacy of twice-yearly ...

His NYC case is now headed to trial April 15, with pre-trial hearings starting March 12. “He has the transcripts [from his first trial], they were made public from five years ago, and he’s got ...

Randomized controlled trials are clinical trials in which at least two interventions — the test treatment and a control treatment — are simultaneously evaluated in two or more arms of the ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

Seven members of the medical team that treated Diego Maradona before his death will today go on trial for homicide in ... tended to the former athlete and clinical physician Pedro Pablo Di Spagna.